Shigan Quantum Technologies Promoters Confirm No Encumbrance on Equity Shares During Financial Year 2025-2026
Shigan Quantum Technologies Limited confirmed that none of its promoters or constituent promoter groups had made any encumbrance, either directly or indirectly, on their respective equity shares in the company during the financial year ended March 31, 2026.The declarations cover various promoter entities and individuals who hold significant equity stakes in the company. The confirmations confirm that all specified holdings remained free from such charges throughout the relevant period.
Details of the promoters and the number of equity shares held by each entity or individual are provided below:
| Promoter/Promoter Group | Shares Held |
|---|---|
| Giridhari Sales Private Limited | 75,75,900 |
| Shigan Autotronics Private Limited | 24,50,000 |
| SA Shigan Trust | 12,75,000 |
| GA Shigan Trust | 13,75,000 |
| Autotronics Worldwide Pte. Ltd. | 12,50,000 |
| Shishir Agrawal | 1,74,975 |
| Gagan Agrawal | 74,975 |
| Santosh Agrawal | 50 |
SHIGAN Stock Price Movement
Shares of Shigan Quantum Technologies Limited settled today at ₹60.00, recording a flat 0.00% change in market activity. The stock recorded a total traded volume of 3,000 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.